FreeCME


Jointly provided by The Leukemia & Lymphoma Society, RMEI Medical Education, LLC, and Postgraduate Institute for Medicine.

 

This activity is supported by independent educational grants from Amgen Inc. and Celgene Corporation. Additional funding provided by The Leukemia & Lymphoma Society.

Specialty: Hematology, Oncology

Activity Purpose: This enduring activity will provide learners with the latest developments in immunotherapy for leukemia, lymphoma, and myeloma and how these developments can be incorporated into regimens to improve the outcome of patients with these diseases.

Target Audience: This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Estimated Time to Complete Activities: 15 minutes for module 1; 30 minutes each for modules 2 through 5; 75 minutes for module 6

 

 

 

 

 

 

 

Faculty

Helen E. Heslop, MD, DSc (Hon)
Dan L. Duncan Chair
Professor, Departments of Medicine and Pediatrics
Director, Center for Cell and Gene Therapy
Associate Director, Clinical Research
Dan L. Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, TX

Carl H. June, MD
Richard W. Vague Professor, Immunotherapy
Director, Center for Cellular Immunotherapies
Director, Parker Institute for Cancer Immunotherapy
University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Hagop M. Kantarjian, MD
Professor and Chair, Department of Leukemia
Samsung Distinguished Leukemia Chair in Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, TX

Ronald Levy, MD
Robert K. and Helen K. Summy Professor
Stanford University School of Medicine
Division of Oncology
Stanford, CA

Yi Lin, MD, PhD
Consultant, Department of Internal Medicine
Consultant, Department of Laboratory Medicine and Pathology
Associate Professor, Medicine
Mayo Clinic Division of Hematology, Rochester, MN
Chair, Cell Therapy Cross-Disciplinary Group
Mayo Clinic Cancer Center

Catherine J. Wu, MD
Professor of Medicine
Dana-Farber Cancer Institute and Harvard Medical School
Institute Member, Broad Institute of Harvard and MIT
Boston, MA